Alx Oncology Holdings (ALXO)
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing cancer therapies for patients in the United States. Its lead candidate is evorpacept, a CD47-blocking biologic being studied in combination with other anti-cancer agents. The program includes the ASPEN-06 phase 2 study in gastric and gastroesophageal junction cancer, along with multiple collaboration-based trials in breast cancer, solid tumors, lymphoma, and multiple myeloma. These partnerships involve Jazz Pharmaceuticals, an antibody-drug conjugate program with fam-trastuzumab deruxtecan-nxki, ALX2004, MD Anderson Cancer Center, and Sanofi. The company also has license agreements with the Board of Trustees of Leland Stanford Junior University. Incorporated in 2015, ALX Oncology is headquartered in South San Francisco, California, and its common stock trades on Nasdaq under the symbol ALXO.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ALXO
|
$1.93
|
20.8% Upside
|
Undervalued
|
$4.60
|
187.5% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
1.7x
|
221.2 M
|
87.202 M
|
4.6%
|
68.5%
|
-1.8
|
87.7%
|
